- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
The share will be traded under the same ticker symbol, OASM, ISIN SE0000722365. No new shares will be issued in conjunction with the listing.
It is very gratifying that Oasmia has been admitted to trading on NASDAQ OMX Stockholm. We assess that NASDAQ OMX Stockholm is a more appropriate market place for the Company's share and regards the list change as a natural step in the Company's development. The admission to trading is a recognition of Oasmia's high standards which facilitate a broadening of the ownership base and improved liquidity in the share. We expect that the list exchange, through increased interest in the Company from the equity market, customers, partners and other interested parties will be beneficial for the Company's continued development says Oasmia's CEO Julian Aleksov.
Oasmia has, in conjunction with the application for admission to trading, prepared a Swedish prospectus which is available on the Company's website, www.oasmia.se.
The prospectus contains, among other things, information, which has not been previously announced, in relation to the Company's planned investments in tangible fixed assets as well as details about license and distribution agreements.
A number of risk factors, which may affect the Company's development, are also presented in the prospectus. Potential investors should consider these risk factors as well as all other information contained in the prospectus.
DisclaimerThis press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of Oasmia's securities. Specifically, the risks and uncertainties that could affect the development of Paccal® Vet include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with Paccal® Vet in particular, including, without limitation, the potential for Paccal® Vet to be proved safe and effective (or to achieve response rates) for the treatment of the indications noted in this press release or any other indication, determinations by regulatory, patent and administrative governmental authorities, the potential that Paccal® Vet will not produce high rates of complete remission in patients with mastocytoma, the possibility that the registration trial for Paccal® Vet as a treatment for mastocytoma in dogs will not occur, the possibility that the U.S. Food and Drug Administration will not approve a phase III registration strategy for Paccal® Vet if proposed by Oasmia, the potential that Abbott will not exercise its distribution rights, Oasmia's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, and costs of developing, producing and supplying Paccal® Vet. Except as may be required by law, Oasmia does not intend to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops second and third generation cancer drugs based on nanotechnology for human and veterinary use. The broad portfolio is focused on oncology and contains several promising products in clinical and pre-clinical phase. Oasmia cooperates with leading universities and other biotech companies to discover and optimize substances with a favorable safety profile and better efficacy. The company name was registered in 1999 and is based in Uppsala, Sweden.
For more information, please click here
Head of Public Relations
Oasmia Pharmaceutical AB.
Phone: +46 (0) 18 50 54 40.
Copyright © Oasmia Pharmaceutical ABIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Nanometrics Reports Second Quarter 2016 Financial Results July 26th, 2016
Nanobiotix revenue for Q2 2016 July 14th, 2016